K22 is an antiviral agent.1 It inhibits the replication of severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus 229E (HCoV-229E), feline coronavirus (FCoV), and mouse hepatitis virus (MHV) in Vero cells when used at a concentration of 40 µM. K22 inhibits the formation of double membrane vesicles, a hallmark of coronavirus replication, and inhibits viral RNA synthesis in HCoV-229E-infected MRC-5 cells. It also reduces viral titers in cells infected with various Arteriviridae or Torovirinae viruses.2
1.Lundin, A., Dijkman, R., BergstrÖm, T., et al.Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virusPLoS Pathog.10(5)e1004166(2014) 2.Rappe, J.C.F., de Wilde, A., Di, H., et al.Antiviral activity of K22 against members of the order NidoviralesVirus Res.24628-34(2018)